MiMedx Group (NASDAQ:MDXG) Reaches New 1-Year Low – Here’s Why

MiMedx Group, Inc (NASDAQ:MDXG)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $5.13 and last traded at $5.2050, with a volume of 240768 shares changing hands. The stock had previously closed at $5.30.

Analyst Ratings Changes

A number of research firms have commented on MDXG. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Wall Street Zen raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Lake Street Capital dropped their target price on MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 20th. Finally, Mizuho lowered their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, MiMedx Group presently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

MiMedx Group Price Performance

The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The company has a 50-day moving average of $6.51 and a 200-day moving average of $6.85. The stock has a market capitalization of $772.35 million, a price-to-earnings ratio of 19.31 and a beta of 1.57.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.08. The firm had revenue of $113.73 million during the quarter, compared to the consensus estimate of $94.74 million. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. As a group, equities research analysts expect that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

Insider Transactions at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total transaction of $432,586.00. Following the completion of the transaction, the insider owned 236,982 shares of the company’s stock, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On MiMedx Group

Several hedge funds and other institutional investors have recently bought and sold shares of MDXG. CWM LLC grew its position in shares of MiMedx Group by 63.8% during the second quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after acquiring an additional 1,892 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in MiMedx Group by 1,808.4% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock valued at $46,000 after acquiring an additional 7,107 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in MiMedx Group during the 3rd quarter worth $54,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of MiMedx Group during the third quarter valued at $84,000. Finally, Allianz Asset Management GmbH bought a new stake in shares of MiMedx Group during the third quarter valued at about $82,000. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.